FDA Prioritizes Shortages Post-Pandemic
US Agency On Resuming Normal Manufacturing Operations When COVID-19 Recedes
Guidance from the FDA urges a focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches when the coronavirus pandemic recedes.
You may also be interested in...
How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.
The US Food and Drug Administration has issued final guidance aimed at encouraging manufacturers of so-called "medically necessary drug products" and their raw materials and components to develop contingency production plans for use during emergencies that result in high absenteeism at production facilities.
Under pressure to authorize use of Lilly’s bamlanivimab, the FDA must first weigh efficacy signals and GMP plant remediation progress.